Using ultra-high frequency ultrasound to diagnose Sjögren's syndrome

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study involves patients diagnosed with Sjögren's syndrome according to established criteria. It aims to enhance diagnostic accuracy by utilizing ultra-high frequency ultrasonography (70 MHz) to assess minor salivary glands, alongside conventional ultrasonography of major salivary glands. The scans will be evaluated using the OMERACT scoring system to determine glandular alterations. The study seeks to improve the sensitivity of Sjögren's syndrome diagnosis through advanced imaging techniques.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* adults ≥ 18 years of age
* clinical suspect of Sjogren\'s syndrome
* acceptance to undergo complete Sjogren\'s Syndrome diagnostic work-up
* acceptance to be included in the study.

Exclusion Criteria:

* pregnancy or breastfeeding
* any acute or chronic condition that would limit the ability of the patient to participate in the study
* refusal to give informed consent

Where it's running

• University of Pisa
  Pisa, Italy Recruiting

Study contacts

• Study coordinator: Rossana Izzetti
• Email: rossana.izzetti@unipi.it
• Phone: +39050993037

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Pain patterns in rheumatic diseases: see if pain works differently in patients and healthy people

  This observational study tests how pain is experienced and measured in people with rheumatic diseases compared with healthy volunteers.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07829497

• First-in-human test of CND319 in healthy people and people with rheumatic diseases

  This early study tests whether CND319 is safe and tolerable and whether it shows any signs of activity in healthy adults and in people with rheumatoid arthritis or Sjogren's syndrome.

  Recruiting Phase 1 Candid Therapeutics · Melbourne, Victoria · NCT07712939

• Tofacitinib safety for people with primary Sjogren disease

  This study will test whether the oral pill tofacitinib is safe and tolerable for adults with primary Sjogren disease and mild-to-moderate symptoms.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07281456

• YTS109 cell therapy for relapsed or refractory autoimmune diseases

  This will try a single infusion of YTS109 immune cells to see if they are safe and help adults 18–65 with relapsed or refractory lupus (including lupus nephritis), Sjogren's syndrome, inflammatory myopathy, or ANCA‑associated vasculitis.

  Recruiting Phase 1 China Immunotech (Beijing) Biotechnology Co., Ltd. · Bengbu · NCT07236762

• Creating Health online course for people with rheumatological conditions

  This project will test whether an online course about diet and self-care helps adults with rheumatoid arthritis, Sjogren's syndrome, lupus, mixed connective tissue disease, or psoriatic arthritis reduce fatigue and improve quality of life.

  Recruiting University of Iowa · Iowa City, Iowa · NCT07180537

• 68Ga-FAPI PET-CT to image inflammation in Sjögren's syndrome

  This trial will test whether 68Ga-FAPI PET-CT can show active inflammation in adults with Sjögren's syndrome compared with tumor patients.

  Recruiting Phase 1/2 Peking Union Medical College Hospital · Beijing · NCT07062523

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.